Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444404 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 820 in Subjects With Advanced Solid Tumors
A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by AmMax Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT01444404 is a Phase 1 study of Cancer and Advanced Solid Tumors that has completed, run by AmMax Bio. The registered enrollment target is 25 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01444404, a Phase 1 study of Cancer and Advanced Solid Tumors, has completed, sponsored by AmMax Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG AMG 820
Study Locations (3)
Pennsylvania
- Research Site - Philadelphia
South Carolina
- Research Site - Greenville
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-03-31 |
| Est. Completion | 2014-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01444404
The ClinicalTrials.gov registry entry for NCT01444404 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is AmMax Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which AMG 820 is the first listed.
NCT01444404 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT01444404 about?
NCT01444404 is a clinical study titled "A Study of AMG 820 in Subjects With Advanced Solid Tumors". First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.
What is the current status of trial NCT01444404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03-31. Estimated completion is 2014-02-06.
What conditions does trial NCT01444404 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors, Oncology, Tumors, Oncology Patients.
What interventions are being tested in trial NCT01444404?
The interventions under investigation include: AMG 820 (DRUG).
Who is sponsoring clinical trial NCT01444404?
This trial is sponsored by AmMax Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01444404 being conducted?
This trial has 3 study locations across Pennsylvania, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.